Mavacamten: First Approval

Mavacamten (Camzyos™) is an oral small-molecule cardiac myosin inhibitor developed by MyoKardia, Inc., a wholly owned subsidiary of Bristol Myers Squibb, for the treatment of hypertrophic cardiomyopathy (HCM) and diseases of diastolic dysfunction. In April 2022, mavacamten was approved for use in th...

Descripción completa

Detalles Bibliográficos
Autor principal: Keam, Susan J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
AdisInsight Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9338109/
https://www.ncbi.nlm.nih.gov/pubmed/35802255
http://dx.doi.org/10.1007/s40265-022-01739-7
_version_ 1784759897136562176
author Keam, Susan J.
author_facet Keam, Susan J.
author_sort Keam, Susan J.
collection PubMed
description Mavacamten (Camzyos™) is an oral small-molecule cardiac myosin inhibitor developed by MyoKardia, Inc., a wholly owned subsidiary of Bristol Myers Squibb, for the treatment of hypertrophic cardiomyopathy (HCM) and diseases of diastolic dysfunction. In April 2022, mavacamten was approved for use in the USA in the treatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive HCM to improve functional capacity and symptoms. This article summarizes the milestones in the development of mavacamten leading to this first approval for the treatment of adults with symptomatic NYHA class II-III obstructive HCM. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40265-022-01739-7.
format Online
Article
Text
id pubmed-9338109
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-93381092022-07-31 Mavacamten: First Approval Keam, Susan J. Drugs AdisInsight Report Mavacamten (Camzyos™) is an oral small-molecule cardiac myosin inhibitor developed by MyoKardia, Inc., a wholly owned subsidiary of Bristol Myers Squibb, for the treatment of hypertrophic cardiomyopathy (HCM) and diseases of diastolic dysfunction. In April 2022, mavacamten was approved for use in the USA in the treatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive HCM to improve functional capacity and symptoms. This article summarizes the milestones in the development of mavacamten leading to this first approval for the treatment of adults with symptomatic NYHA class II-III obstructive HCM. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40265-022-01739-7. Springer International Publishing 2022-07-08 2022 /pmc/articles/PMC9338109/ /pubmed/35802255 http://dx.doi.org/10.1007/s40265-022-01739-7 Text en © Springer Nature 2022, corrected publication 2022 https://creativecommons.org/licenses/by-nc/4.0/Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle AdisInsight Report
Keam, Susan J.
Mavacamten: First Approval
title Mavacamten: First Approval
title_full Mavacamten: First Approval
title_fullStr Mavacamten: First Approval
title_full_unstemmed Mavacamten: First Approval
title_short Mavacamten: First Approval
title_sort mavacamten: first approval
topic AdisInsight Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9338109/
https://www.ncbi.nlm.nih.gov/pubmed/35802255
http://dx.doi.org/10.1007/s40265-022-01739-7
work_keys_str_mv AT keamsusanj mavacamtenfirstapproval

Ejemplares similares